Zydus Lifesciences launches drug for treating bad cholesterol

Zydus Lifesciences launches drug for treating bad cholesterol

Zydus Lifesciences launches drug for treating bad cholesterol Bemdac (Bempedoic acid) is a new class of drug which is orally administered and offers a new line of treatment for patients suffering from uncontrolled levels of LDL-Cholesterol (LDL-c) despite lifestyle modifications and the use of maximum tolerated dose of statins, which form the cornerstone of dyslipidemia management, the company…

View On WordPress

Walk-in Interview at Bengaluru on 05/05/2024, Sunday for (USP/DSP/QMS) Production department for Zydus Biologics (Zydus Biotech Park) R&d - Zrc|zyd.biologics-2, Ahmedabad, Gujarat, India APPLY FOR THIS JOBSHARE Division: BIOLOGICS - III Employee Type: P-P7-Probationer-HO Staff Experience range (Years): 1 year - 10 years Inviting candidates for a walk-in interview for (USP/DSP/QMS) Production department for Zydus Biologics (Zydus Biotech Park) on 5th May 2024, Sunday from 9:00 am to 5:00 pm (The interviews will take place at Bengaluru) USP Production: Executive/Senior Executive/ Assistant Manager: Executive/Senior Executive/ Assistant Manager: M.Sc./ B. Tech/B. E/ M. Tech – Biotechnology/Biochemistry with 3 – 10 years of experience in handling of large-scale mammalian cell culture (SS bioreactor), media/feed preparation and its filtration. The job requires readiness of bioreactor and associated vessels (CIP, FIT, PHT, SIP), operation of bioreactor & associated vessels, readiness and operation of centrifuge, clarification of cells for manufacturing of monoclonal antibodies/ bio therapeutic protein. DSP Production: Executive/ Senior Executive/ Assistant Manager: M.Sc./B.Tech/ B. E/ M. Tech – Biotechnology/Biochemistry Candidates with 3-10 years of experience in downstream purification process for recombinant products, TFF system, chromatography system, virus filtration procedures and CIP/SIP of the equipment. QMS Production: Executive/ Senior Executive/ Associate Manager: M.Sc./B.Tech/ B. E/ M. Tech – Biotechnology/Biochemistry Candidates with 3-15 years of experience in Preparation of risk assessment and investigation report. Meetings with cross functional team to identify the root causes of deviation, OOT and OOS. Initiation and/or review, closing of the QMS document such as deviation, change control and CAPA using Trackwise or similar software. Regular discussion with manufacturing team to reduce the human errors which leads to deviation. Preparation and/ or review of cGMP documents such as MFR, BMR, SOP etc. For all above positions, candidates having exposure to regulatory requirement of documentation and cGMP/GLP is essential. Preference will be given to those who have thorough knowledge of all the manufacturing operations of Biosimilar products. [caption id="attachment_58045" align="aligncenter" width="930"] Zydus Lifesciences Recruitment Notification[/caption] ------------------------------------------------------------------------------------------------------------- Note: (1) All the employees will be working in shifts according to work allocation. (2) The shift deployment for Male Candidates will be A/B/C. Candidates can walk in with a recent copy of their resume with copies of relevant qualification certificates/mark sheets, PAN Card, Aadhar Card, Latest increment letter, experience letter of previous organizations if any, and salary slips for the last 3 Months. ---------------------------------------------------------------------------------------------------------------------------------- Walk-in Venue: Starlit Suites Hotel E 39/275, Smondoville Road, Neotown, Electronic City, Bengaluru, Bommasandra, Karnataka 560100 Contact No: 08043403333

Zydus Lifesciences walk in interview for FRESHERS on 20th April, 2024

Zydus Lifesciences walk in interview for FRESHERS on 20th April, 2024 Inviting candidates for a walk-in interview for Oncology department at SEZ 1. Ahmedabad on 20th April, 2024 from 9:30 am to 3:30 pm Oncology department Fresher: Candidates should have B.Sc., B.Pharm, Diploma Graduates, B.E. / B.Tech backgrounds and should have graduated in the years 2022, 2023 and 2024. Candidates who have…

View On WordPress

Chronic Obstructive Pulmonary Disease (COPD) Market is projected to experience growth by 2032, analyses DelveInsight | Afimmune, Allakos, Amgen/AstraZeneca, Arrowhead Pharmaceutical, Zydus Lifescience

http://dlvr.it/T5Mmgf

Top 10 Veterinary PCD Companies in Haryana

When it comes to veterinary healthcare, Haryana boasts several reputable companies that specialize in providing high-quality products and services. In this article, we will explore the top 10 veterinary PCD (Propaganda Cum Distribution) companies in Haryana that have gained recognition for their excellence in beast healthcare.

Orison Pharmaceuticals:

Orison Pharmaceuticals stands out among the top veterinary PCD companies in Haryana. With a commitment to quality and innovation, they have established themselves as a trusted name in the industry . Their range of veterinary products caters to various animal health needs, ensuring the well-being of pets and livestock alike .

Biotique Healthcare:

Biotique Healthcare is another prominent player in the field of veterinary PCD companies. Known for their legacy of excellence, they offer a wide range of pharmaceutical products for animals . Their dedication to research and development has enabled them to provide effective solutions for animal health issues.

Estemax Biotech:

Estemax Biotech is recognized as a reliable partner in veterinary healthcare . They prioritize customer satisfaction by delivering high-quality products that meet international standards. With their extensive product portfolio, they cater to diverse animal health requirements.

Watson Healthcare:

Watson Healthcare has made its mark as one of the leading veterinary PCD companies in Haryana . They are known for their commitment to producing safe and effective medicines for animals. Their range includes pharmaceuticals, feed supplements, and nutritional products.

Zydus Animal Health:

Zydus Animal Health is dedicated to improving animal health through innovative solutions . They offer a comprehensive range of pharmaceuticals and vaccines that address various diseases and conditions in animals. Their products are trusted by veterinarians and animal owners alike.

Reticine PharmAids Limited:

Reticine PharmAids Limited is a key player in the veterinary PCD industry . They specialize in manufacturing and distributing a wide range of veterinary medicines, feed supplements, and healthcare products. With their commitment to quality, they have gained the trust of veterinarians across Haryana.

Vetnation Pharmaceuticals:

Vetnation Pharmaceuticals is known for its extensive product range catering to different species of animals . They prioritize animal welfare and offer high-quality pharmaceuticals that meet the specific needs of pets, livestock, and poultry.

Vetraise Lifesciences:

Vetraise Lifesciences is committed to providing innovative solutions for animal health . They offer a diverse range of veterinary pharmaceuticals, vaccines, and nutritional supplements. Their products are formulated using advanced technology to ensure optimal results.

Veterinary Healthcare Solutions:

Veterinary Healthcare Solutions focuses on delivering reliable healthcare solutions for animals . They offer a comprehensive range of veterinary pharmaceuticals, nutraceuticals, and feed supplements that promote animal well-being.

Animal Care Pharmaceuticals:

Animal Care Pharmaceuticals completes our list of top 10 veterinary PCD companies in Haryana . They specialize in manufacturing high-quality veterinary medicines that cater to various animal health needs.

Conclusion:

The top 10 veterinary PCD companies in Haryana play a crucial role in ensuring the health and well-being of animals across the region. Through their commitment to excellence, innovation, and customer satisfaction, these companies have established themselves as leaders in beast healthcare

A Market on the Move: Exploring Investment Opportunities in Global Painkillers Market

the global painkillers market growth is anticipated to be valued at US$ 100.9 billion by the end of 2033 and US$ 70.0 billion by the end of 2023. According to a new projection by Future Market Insights, opioids will command the highest price on the global market in 2022, with a share of roughly 53.4%. The regulatory landscape surrounding painkillers has a significant effect on the growth of the industry. These regulations are required to safeguard patient safety and prevent the misuse and overuse of painkillers, but if there are too many of them, people may not be able to get the right pain treatment.

Get a Sample Copy of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-17075

Increased attention in recent years has led to stricter controls and prohibitions on the use of opiate painkillers. This has created an opportunity for non-narcotic painkillers, such as NSAIDs (non-steroidal anti-inflammatory pharmaceuticals), and other non-narcotic medications, to gain market share. Alternative pain management solutions could be offered by businesses in response to regulatory efforts to improve pain management and reduce opioid abuse, such as physician education initiatives and prescription drug monitoring systems. A number of leading pharmaceutical companies consistently prioritize clinical breakthroughs in the formulation and administration of analgesic drugs. They are also developing safer opioids that effectively manage pain and have fewer adverse effects.

The creation of analgesic formulations with abuse-deterrent qualities that are more challenging to manipulate for snorting or injection — the methods of administration most frequently associated with addiction due to their rewarding effects — is perhaps the most notable clinical improvement.

Key Players:

AbbVie Inc. (Allergan plc)

Bristol Myers Squibb Co.

Sanofi S.A.

Boehringer Ingelheim International GmbH

Pfizer Inc.

Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)

GSK plc.

Others

Key Market Segments Covered in Painkillers Industry Research

By Drug Class:

Opioids

Tramadol

Oxycodone

Hydrocodone

Other Opioids

NSAIDs

Local Anesthetics

Acetaminophen

By Product:

OTC Products

Prescription Drugs

By Indication:

Surgical Pain

Cancer Pain

Neuropathic Pain

Musculoskeletal and Joint Pain

Others

By Route of Administration:

Injectable

Oral

Rectal

Topical

Transdermal

Others

By Distribution Channel:

Hospital Pharmacies

Specialty Clinics

Long-Term Care Centers

Retail Pharmacies

Drug Stores

Online Pharmacies

Human Chorionic Gonadotropin (HCG) Market is Estimated To Witness High Growth Owing To Rise in Infertility Rates

Human chorionic gonadotropin or HCG hormone is produced during pregnancy in women. It supports the normal development of an egg in a woman's ovary, and the egg is released from the ovary during ovulation. HCG hormone is also used medically to stimulate ovulation and pregnancy in infertile women. The use of HCG hormone encourages the healthy development of the early stages of pregnancy. The Human Chorionic Gonadotropin (HCG) Market is estimated to be valued at US$ 710.88 Mn or Million in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market key trends: The global HCG market is mainly driven by rising rates of infertility worldwide. In 2020, infertility was estimated to affect around 186 million people globally. Male infertility contributed to around 20-30% of infertility cases and female infertility contributed to 40-55% of cases. The remaining cases were due to combined problems or unknown causes. The rising infertility levels have led to increasing adoption of assisted reproductive technologies (ART) like HCG treatment. Besides this, increasing awareness about infertility treatment options and growing acceptability of HCG hormone for fertility treatment are fueling the growth of the human chorionic gonadotropin market. However, side effects associated with HCG therapy and availability of alternative therapies may hamper market growth over the forecast period. Porter’s Analysis Threat of new entrants: The Human Chorionic Gonadotropin (HCG) market requires high capital investment and has the presence of well-established players. This makes the threat of new entrants low. Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of alternative products. However, the established therapies offer value to the patients. Bargaining power of suppliers: A few major suppliers dominate the raw material supply chain. This gives them moderate bargaining power. Threat of new substitutes: The Threat from substitutes is moderate as alternate established therapies offer comparable effectiveness. Competitive rivalry: The competition is high among existing players. SWOT Analysis Strength: Wide application areas and proven benefits of HCG Drive demand. Established distribution channels of major players. Weakness: Strict regulations and compliance requirements add production costs. Short shelf life is a concern. Opportunity: Increasing fertility disorders prevalence provides untapped growth potential regions. Novel drug delivery methods can boost customer acceptance. Threats: Price erosion due to patent expiries and entry of biosimilars. Stringent manufacturing practices up costs. Key Takeaways The global Human Chorionic Gonadotropin (HCG) market is expected to witness high growth, exhibiting CAGR of 6.5% over the forecast period, due to increasing prevalence of fertility-related issues. Advancements in assisted reproductive technologies and rising disposable income also support the market expansion. Regionally, North America dominated the HCG market in 2023 with over 30% revenue share owing to well-developed healthcare infrastructure and growing healthcare spending. Asia Pacific is anticipated to exhibit fastest growth during 2023-2030 induced by surging medical tourism, rising focus on infertility treatments, and growing generic drugs market in India and China. Key players operating in the Human Chorionic Gonadotropin market are Merck & Co., Inc., Ferring B.V.,Fresenius SE & Co.KGaA,Lupin,Sun Pharmaceutical Industries Ltd,Lee BioSolutions,Serum Institute of India Pvt. Ltd., Scripps Laboratories,Sanzyme Biologics Pvt. Ltd.,VHB Medi Sciences Limited, Bharat Serums And Vaccines Limited (BSV), Zydus Lifesciences Ltd, Corona Remedies Pvt. Ltd.

A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol

For the first time in India, Zydus Lifesciences Ltd. (formerly Cadila Healthcare Ltd) has launched a new class of drug 'Bemdac' to treat uncontrolled low density lipoprotein cholesterol (LDL-c).

With uncontrolled LDL-c posing a major risk of developing cardiovascular diseases, the same was lacking proper treatment despite patients' life-style modifications and use of maximum tolerated dose of statins. However, now addressing the pressing healthcare need, the oral drug Bemdac will offer a new line of treatment for patients from uncontrolled levels of LDL-c.

Often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels, LDL-c increases the chances of health problems such as heart attack or stroke.

Uncontrolled LDL-c currently leads to imbalance of lipids including cholesterol, LDL-c, triglycerides and high-density lipoprotein (HDL), commonly known as dyslipidemia. Citing various studies, Zydus Lifesciences on Friday stated that eight out of 10 Indians are dyslipidemic and 112 million adults suffer from high levels of LDL-c.

Moreover, seven out of 10 dyslipidemia patients who are on statin treatment continue to suffer from uncontrolled LDL-c. Besides, 5.4 million Indians are found to be intolerant to statin therapy. However, Bemdac's Bempedoic acid has also shown to have good results in patients not able to tolerate statins and those who do not respond to statins.

Anemia In Chronic Kidney Disease Market to Witness Growth by 2032, Estimates DelveInsight | Companies – Sun Pharmaceutical Industries, Zydus Lifesciences

http://dlvr.it/SyTDTm

Zydus Lifesciences, Oral Inhibitor of NLRP3 Inflammasome, for Patients with Amyotrophic Lateral Sclerosis

Zydus Lifesciences Launches Phase II Clinical Trial of ZYIL1, an Innovative Oral Inhibitor of NLRP3 Inflammasome, for Patients with Amyotrophic Lateral Sclerosis The Phase 2 clinical trial will assess the safety and efficacy of ZYIL1 in Amyotrophic Lateral Sclerosis (ALS) patients [ClinicalTrials.gov ID: NCT05981040] ALS is a rare, progressive and fatal neurodegenerative disease, with an average…

View On WordPress

Are you a D Pharmacy or B Pharm fresher eager to kickstart your career in the pharmaceutical industry? Zydus Lifesciences in Vadodara is offering exciting opportunities across various departments, including Production, Packing, Warehouse, QA, QC, and Engineering. As a leading player in the pharmaceutical sector, Zydus Lifesciences is committed to fostering innovation and nurturing talent. About Zydus Lifesciences: Zydus Lifesciences, based in Vadodara, is a renowned pharmaceutical company dedicated to improving healthcare outcomes. Established with a vision to deliver high-quality healthcare solutions, the company has grown into a powerhouse of innovation and excellence. Founded by visionary leaders, Zydus Lifesciences boasts a culture that values collaboration, integrity, and continuous learning. Zydus Lifesciences Vacancies: Explore our vacancies across various departments: Production Apprentice Aseptic Filling, Vial Washing/Tunnel/Capping, Packing, Visual Inspection Qualifications: 10th/12th/ITI – AOCP, MMCP, COPA/D.Pharm/B.Pharm (Government college only) Engineering Apprentice Electrical, Mechanical, Instrumentation Qualifications: Diploma/ITI – Electrical, MMCP, RFM, Instrumentation, Fitter (Government college only) FTE (Full-Time Equivalent) Positions Production & Packing Qualifications: 10th/12th/ITI with 1 to 2 years of relevant experience [caption id="attachment_58045" align="aligncenter" width="930"] Zydus Lifesciences Recruitment Notification[/caption] Job Description: Role: Apprentice/FTE Industry Type: Pharmaceutical Department: Production, Packing, Warehouse, QA, QC, Engineering Employment Type: Fixed Term, Full-Time Equivalent Role Category: Manufacturing/Engineering Educational Background Required: D Pharmacy, B Pharm, ITI, Diploma (as specified for each role) Key Skills: Autoclave Operation, Compounding, Visual Inspection, Electrical/Mechanical/Instrumentation skills, etc. How to Apply: Interested candidates meeting the specified qualifications can apply

Zydus Lifesciences - Walk-in drive for ITI, Diploma, BA, B Com, BSc, MSc, B Pharm, M Pharm on 8th Oct 2023

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality…

View On WordPress

"Breaking News: Zydus Achieves USFDA's Green Light for Breakthrough Erythromycin Tablets - Discover the Game-Changing Innovation Unleashing a New Era of Treatment!"

Zydus Lifesciences Limited, along with its subsidiaries and affiliates, has announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Erythromycin Tablets USP in 250 mg and 500 mg dosages. This medication is an antibacterial product used to prevent and treat various infections in different parts of the body, including respiratory tract…

View On WordPress

"Breaking News: Zydus Achieves USFDA's Green Light for Breakthrough Erythromycin Tablets - Discover the Game-Changing Innovation Unleashing a New Era of Treatment!"

Zydus Lifesciences Limited, along with its subsidiaries and affiliates, has announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Erythromycin Tablets USP in 250 mg and 500 mg dosages. This medication is an antibacterial product used to prevent and treat various infections in different parts of the body, including respiratory tract…

View On WordPress

"Breaking News: Zydus Achieves USFDA's Green Light for Breakthrough Erythromycin Tablets - Discover the Game-Changing Innovation Unleashing a New Era of Treatment!"

Zydus Lifesciences Limited, along with its subsidiaries and affiliates, has announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Erythromycin Tablets USP in 250 mg and 500 mg dosages. This medication is an antibacterial product used to prevent and treat various infections in different parts of the body, including respiratory tract…

View On WordPress